Cargando…

Parkinson’s: a syndrome rather than a disease?

Emerging concepts suggest that a multitude of pathology ranging from misfolding of alpha-synuclein to neuroinflammation, mitochondrial dysfunction, and neurotransmitter driven alteration of brain neuronal networks lead to a syndrome that is commonly known as Parkinson’s disease. The complex underlyi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Titova, Nataliya, Padmakumar, C., Lewis, Simon J. G., Chaudhuri, K. Ray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2016
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514217/ https://www.ncbi.nlm.nih.gov/pubmed/28028643 http://dx.doi.org/10.1007/s00702-016-1667-6

Ejemplares similares

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Editorial: Movement Disorders and Sleep – Underlying Mechanisms, Clinical Aspects and Treatment
por: Falup-Pecurariu, Cristian, et al.
Publicado: (2019)

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Do We Belittle Essential Tremor by Calling It a Syndrome Rather Than a Disease? No
por: Elble, Rodger J.
Publicado: (2020)

Do We Belittle Essential Tremor by Calling It a Syndrome Rather Than a Disease? Yes
por: Lenka, Abhishek, et al.
Publicado: (2020)

Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Dry eye in Parkinson's disease: a narrative review
por: Ungureanu, Larisa, et al.
Publicado: (2023)

Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
por: Sportelli, Carolina, et al.
Publicado: (2020)

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
por: Titova, Nataliya, et al.
Publicado: (2017)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2019)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Corticobasal syndrome and Parkinson’s disease at the beginning: asymmetrical patterns of MRI and Blink Reflex for early diagnosis
por: Donzuso, Giulia, et al.
Publicado: (2022)

Disease modification in Parkinsonism: obstacles and ways forward
por: Höllerhage, M., et al.
Publicado: (2022)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Small intestine dysfunction in Parkinson’s disease
por: Dutkiewicz, Justyna, et al.
Publicado: (2015)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

Risky decision-making and affective features of impulse control disorders in Parkinson’s disease
por: Martini, Alice, et al.
Publicado: (2017)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Wilful pathogens provoke a gut feeling in Parkinson’s disease
por: Sian-Hülsmann, Jeswinder
Publicado: (2021)

Sleep and non-motor symptoms in Parkinson’s disease
por: Maass, Antonia, et al.
Publicado: (2013)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

Magnetic resonance imaging for the diagnosis of Parkinson’s disease
por: Heim, Beatrice, et al.
Publicado: (2017)

Genetic testing for Parkinson’s disease in clinical practice
por: Gasser, Thomas
Publicado: (2023)

The use of wearables for the diagnosis and treatment of Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2023)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Parkinson’s disease therapy: what lies ahead?
por: Wolff, Andreas, et al.
Publicado: (2023)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Non-motor symptoms of Parkinson’s disease: the patient’s perspective
por: Breen, Kieran C., et al.
Publicado: (2012)

Flavor perception and the risk of malnutrition in patients with Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2018)

Diagnostic accuracy of glabellar tap sign for Parkinson’s disease
por: Nuuttila, Simo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_im9k3ulhnn0enr7qn31mdf3fu3